Action LLY ELI LILLY AND COMPANY
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Eli Lilly and Company Xetra

Actions

LLY

US5324571083

Temps réel estimé Tradegate
Autres places de cotation
 16:21:23 17/07/2024 		Varia. 5j. Varia. 1 janv.
836 EUR -4,14 % Graphique intraday de Eli Lilly and Company -4,08 % +58,07 %
14:49 Spirit Airlines : Johnson & Johnson, Omnicom, VF Corporation... les valeurs à suivre aujourd'hui à Wall Street - AO
14:22 Eli Lilly and : attendu en baisse après les résultats positifs de Roche contre l'obésité AO

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene
AQ
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion - InsideArbitrage
AQ
Weight loss drug Zepbound outperforms Ozempic in new published study
AQ
Lilly agrees $3.2b IBD acquisition
AQ
Tesla, Archer Aviation rise; Eli Lilly falls, Tuesday, 7/2/2024
AQ
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
AQ
Augustine Therapeutics announces EUR17 million Series A1 financing round
AQ
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
PR
Lilly Declares Third-Quarter 2024 Dividend
PR
WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs
AQ
Eli Lilly and : Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products
PU
Eli Lilly and : An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro® and Zepbound®
PU
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
PR
Lilly announces departure of Anat Ashkenazi, chief financial officer
PR
Eli Lilly and Company - Melissa Seymour to join Lilly as executive vice president of Global Quality
AQ
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
AQ
Eli Lilly and : Asco Lilly Oncology Presentation
PU
AKTIS ONCOLOGY NAMES TYLER BENEDUM, Ph.D., CHIEF TECHNICAL OFFICER
AQ
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
PR
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action LLY
  4. Action LLY
  5. Actualités Eli Lilly and Company
  6. Communiqués